HC Wainwright Weighs in on FibroGen FY2026 Earnings

FibroGen, Inc. (NASDAQ:FGEN) – HC Wainwright issued their FY2026 earnings per share (EPS) estimates for shares of FibroGen in a research note issued to investors on Tuesday, December 17th. HC Wainwright analyst M. Keller forecasts that the biopharmaceutical company will post earnings per share of ($0.56) for the year. The consensus estimate for FibroGen’s current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for FibroGen’s FY2027 earnings at ($0.44) EPS and FY2028 earnings at ($0.44) EPS.

FibroGen (NASDAQ:FGEN) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.21. The company had revenue of $46.33 million for the quarter, compared to analysts’ expectations of $34.00 million. During the same period in the prior year, the company earned ($0.52) earnings per share.

A number of other analysts have also issued reports on the company. William Blair restated a “market perform” rating on shares of FibroGen in a report on Wednesday, November 13th. StockNews.com began coverage on FibroGen in a research note on Monday. They issued a “hold” rating for the company.

FibroGen Stock Performance

Shares of NASDAQ:FGEN opened at $0.35 on Wednesday. The firm has a 50 day simple moving average of $0.35 and a 200 day simple moving average of $0.58. FibroGen has a 52 week low of $0.18 and a 52 week high of $2.93. The company has a market cap of $35.08 million, a PE ratio of -0.28 and a beta of 0.82.

Hedge Funds Weigh In On FibroGen

Several institutional investors and hedge funds have recently modified their holdings of the stock. Cubist Systematic Strategies LLC raised its holdings in shares of FibroGen by 3,906.9% during the second quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 280,161 shares in the last quarter. Point72 DIFC Ltd raised its stake in shares of FibroGen by 734.2% during the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 45,990 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of FibroGen during the 2nd quarter valued at about $424,000. Acadian Asset Management LLC grew its stake in shares of FibroGen by 34.4% in the 2nd quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock valued at $2,997,000 after buying an additional 860,854 shares in the last quarter. Finally, Sei Investments Co. increased its holdings in FibroGen by 38.4% in the second quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 41,442 shares during the last quarter. 72.71% of the stock is currently owned by hedge funds and other institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.